Revvity (RVTY) Total Non-Current Liabilities (2010 - 2026)
Revvity's (RVTY) quarterly Total Non-Current Liabilities came in at $4.0 billion in Q2 2026, down 14.69% YoY from $4.7 billion in Q2 2025, and down 2.37% on a QoQ basis from $4.1 billion in Q4 2025.
Revvity (RVTY) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Revvity (RVTY) has 17 years of Total Non-Current Liabilities data on file, last reported at $4.0 billion in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 14.69% year-over-year to $4.0 billion in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $4.0 billion (down 14.69% YoY) and the FY2025 annual result came in at $4.1 billion, down 12.61% from the prior year.
- Total Non-Current Liabilities declined to $4.0 billion in Q2 2026, from $4.1 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $7.8 billion in Q1 2022 to a low of $4.0 billion in Q3 2024.
- A 5-year average of $5.5 billion and a median of $5.5 billion in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 84.78% — and 2024, when it fell 16.77%.
- Tracing RVTY's Total Non-Current Liabilities over 5 years: stood at $5.5 billion in 2022, then grew by 2.26% to $5.7 billion in 2023, then declined by 16.77% to $4.7 billion in 2024, then slipped by 12.61% to $4.1 billion in 2025, then retreated by 2.37% to $4.0 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.0 billion (Q2 2026), $4.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 108.64 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 85.84 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 542.10 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 5.45 Bn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 22.94 Bn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 737.18 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 6.36 Bn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 3.39 Bn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.88 Bn |
| 10 | Revvity | 12.89 Bn | 12.03 Bn | 387.66 Mn | 4.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 5, 2026 | 4.01 Bn |
| Dec 28, 2025 | 4.11 Bn |
| Sep 28, 2025 | 4.01 Bn |
| Jun 29, 2025 | 4.79 Bn |
| Mar 30, 2025 | 4.70 Bn |
| Dec 29, 2024 | 4.70 Bn |
| Sep 29, 2024 | 4.00 Bn |
| Jun 30, 2024 | 5.52 Bn |
| Mar 31, 2024 | 5.56 Bn |
| Dec 31, 2023 | 5.65 Bn |
| Oct 1, 2023 | 4.73 Bn |
| Jul 2, 2023 | 6.31 Bn |
| Apr 2, 2023 | 6.56 Bn |
| Jan 1, 2023 | 6.70 Bn |
| Oct 2, 2022 | 5.53 Bn |
| Jul 3, 2022 | 6.97 Bn |
| Apr 3, 2022 | 7.61 Bn |
| Jan 2, 2022 | 7.80 Bn |
| Oct 3, 2021 | 6.43 Bn |
| Jul 4, 2021 | 4.50 Bn |